Studying skin lymphoma to find prognostic and treatment targets
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study looks at skin lymphomas (a type of white blood cell cancer that starts in the skin) to find factors that predict how the disease will progress and to identify new ways to treat it. By joining, you help researchers understand and improve treatment for this condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be at least 18 years old
- Have a suspected or confirmed diagnosis of primary cutaneous lymphoma (a lymphoma starting in the skin)
- Be able to sign an informed consent form
- Not be under legal guardianship or curatorship
- Be affiliated with a social security system
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at what treatments work for people with primary cutaneous lymphoma, and how patients do over time. It uses real patient information from participating hospitals to understand outcomes after diagnosis.
This study looks at the bacteria (microbiome) living on the skin in people with specific skin conditions, and in healthy volunteers. The results may help researchers understand what skin microbes have to do with these diseases.
This study collects stored tissue samples (from skin or other needed procedures) from people with CTCL, Sézary syndrome, or lymphomatoid papulosis, especially when you are starting or changing treatment. It’s meant to help researchers learn more about these illnesses and may support future research.
This study aims to understand how common skin lymphomas are in Italy. You might be able to help if you have been diagnosed with a skin lymphoma.
This study collects blood, urine, and possibly small tissue samples to learn more about cutaneous T-cell lymphoma (CTCL) and either eczema or atopic dermatitis. It may help researchers better understand these skin conditions and improve future treatments.
This study looks for “predictive” and “prognostic” biomarkers—measurable signs in blood or tissue—to help predict how mycosis fungoides or Sézary syndrome will behave and how patients may respond to care. It may help doctors better understand outcomes for people with these skin lymphomas.
Hear when a new Cutaneous Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.